Skip to content
Peptide research

Cerebrolysin

Also known as FPF-1070
Category
Brain & Cognition
Administration routes
Injectable
Regulatory status
Not FDA-approved

What it is

Cerebrolysin is a mix of small peptides and amino acids from pig brain protein, used for cognitive decline, stroke, and brain injury. Human evidence is uneven: Alzheimer benefit is well supported, injury and stroke recovery only moderately so, and neuroplasticity claims remain speculative. A 2023 Cochrane review found no stroke mortality benefit and a possible increase in non-fatal serious adverse events, and it is contraindicated in severe renal impairment and status epilepticus, with caution required in other seizure disorders. Not FDA-approved in the US.

Read Full record

Studied uses & evidence

Studied uses(6)

  • Neuroprotection after acute brain injury

    Medium

    Human stroke and TBI trials show no clear survival benefit; strong animal neuroprotection data only.

  • Neuroplasticity enhancement

    Low

    Strong animal evidence for enhanced plasticity; human data limited to indirect cognitive and BDNF signals.

  • Cognitive improvement in Alzheimer disease

    High

    Multiple placebo-controlled human trials show modest cognitive and global benefit, mostly short term.

Evidence limits

Evidence Level
Moderate

Strongest evidence for mild-to-moderate Alzheimer disease (6 RCTs, significant cognitive and global benefits). Promising but heterogeneous evidence for TBI (significant GOS improvement). Mixed evidence for acute ischemic stroke — a 2023 Cochrane review found no benefit for preventing all-cause mortality. Approved in 45+ countries based on available evidence.

Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)

Cautions & risk summary

Do not use if

  • Severe renal impairment

    Absolute

    Contains amino acid fragments that require renal clearance.

  • Epilepsy

    High

    Neurotrophic effects may lower seizure threshold. Use with caution in epilepsy.

General cautions

  • Pregnancy

    High

    Avoid during pregnancy unless clinically required. Animal reproductive studies found no evidence of reproductive toxicity; adequate human pregnancy safety is unestablished.

Risk summary(9)

Risks = level of concern: High · Moderate · Low · Theoretical

  • Not FDA-approved — limited regulatory oversight in the US

    High
  • The 2023 Cochrane review found no mortality benefit and a possible increase in non-fatal serious adverse events after acute ischemic stroke.

    Moderate
  • Contraindicated in epilepsy — may lower seizure threshold

    Moderate
  • Contraindicated in severe renal impairment.

    Moderate
  • Contraindicated in hypersensitivity to porcine-derived biological products

    Moderate
  • Common adverse effects: vertigo, agitation, feeling hot, headache, nausea, sweating (generally mild and transient)

    Low
  • Porcine-derived product carries theoretical risk of allergic reactions or prion concerns (though no cases documented)

    Theoretical
  • Heterogeneous clinical evidence — stroke benefit remains controversial despite widespread international use

    High
  • Lack of standardization concerns: as a biological peptide mixture, batch-to-batch consistency may vary

    Low
Safety & interactions in Full record

Further reading

Read Full record

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.